Palbociclib Capsules

The world's first CDK4/6 targeted inhibitor approved for HR+/HER2-type locally advanced or metastatic breast cancer

Breast cancer is the most common malignant tumor in women, of which HR+/HER2-breast cancer accounts for more than 60%. Palbociclib is the world's first approved CDK4/6 inhibitor, and its emergence opens a new era of endocrine therapy for HR+/HER2-advanced breast cancer. Compared with previous endocrine therapy alone, the combination of Palbociclib significantly extends the survival time of patients.

Indications

Palbociclib capsules are indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: 

- an aromatase inhibitor as initial endocrine-based therapy; or 

- fulvestrant in patients with disease progression following endocrine therapy. 

Palbociclib capsules are indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

Strength

75mg/capsule

100mg/capsule

125mg/capsule